Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2013. The report details a specific share repurchase transaction executed on June 20, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 750,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,654 pence per share; lowest price paid was 1,609 pence per share.
- Treasury Holdings (Settled): 511,602,512 shares (9.42% of total issued share capital).
- Treasury Holdings (Including Unsettled): 513,399,512 shares (10.44% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,918,525,374 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 750,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.44% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure under the Financial Conduct Authority's Disclosure and Transparency Rules regarding share ownership thresholds.
Investor Verification Points
- Verify the total cost of the 750,000 share repurchase based on the weighted average price between 1,609 and 1,654 pence.
- Confirm the impact of the 10.44% Treasury holding on the denominator for calculating shareholder notification thresholds.
- Check subsequent filings for the settlement status of the shares purchased but not yet settled at the time of this report.